The present disclosure generally relates to an aerosol inhalation device, and more particularly, to a valved spacer for a metered-dose inhaler.
Patients with asthma and other lung conditions are frequently prescribed medication that is delivered straight to their lungs as aerosol via a metered-dose inhaler (MDI). Patients who have trouble breathing may use a spacer device in combination with an MDI to help them inhale the aerosolized medication more easily and effectively. For instance, if a patient does not use a proper inhalation technique with a MDI then the desired dose of medication may not reach the lungs. Such patients who cannot properly inhale medication directly from an MDI typically benefit from adding a spacer, which is a type of holding chamber that attaches to the inhaler and slows the delivery of medication.
Conventional spacers make inhalers easier to use and deliver medication more efficiently. However, problems with existing spacers often make it difficult for the patient to inhale the medication into their lungs and subsequently exhale so that the patient can be ready to breathe in additional medication as necessary. Furthermore, the effectiveness of delivery of aerosolized medication to a patient's lungs may be diminished when the patient cannot gauge the timing and speed of their own breathing relative to the activation of the inhaler. This problem is especially apparent when the patient is critically ill and/or very weak and is already having extreme difficulties in breathing. Moreover, since several breaths are often required for an administration of the required drug dosage, conventional spacers that inhibit the flow of exhaled breaths can make it quite difficult for the user to exhale, thus impacting the effectiveness of subsequent inhaled breaths of medication. Therefore, there is a need for an aerosol inhalation device that overcomes these problems as well as many other problems of conventional spacers.
The foregoing needs are met by implementations of an aerosol inhalation device for use with a metered-dose inhaler according to the present disclosure. According to one aspect of the disclosure, an aerosol inhalation spacer for use with a metered-dose inhaler comprises a transparent chamber housing having a body with an input end and an output end and defining an interior space; a mouthpiece connected to the output end of the chamber housing; an inhaler adapter connected to the input end of the chamber housing; and a valve member disposed between the mouthpiece and the output end of the chamber housing, the valve member adapted to cooperate with a portion of the chamber housing to form a one-way inhalation valve and a one-way exhalation valve; the one-way inhalation valve configured to allow a flow of aerosol to pass from the interior space of the chamber housing to the mouthpiece but not to the atmosphere during inhalation, and the one-way exhalation valve configured to allow a flow of exhaled air to pass from the mouthpiece to the atmosphere but not to the interior space of the chamber housing during exhalation.
According to another aspect of the disclosure, the output end of the holding chamber further comprises a flow control member adapted to cooperate with the valve member to form the inhalation and exhalation valves.
According to another aspect of the disclosure, the inhalation valve comprises a one-way inhalation flap valve.
According to another aspect of the disclosure, the exhalation valve comprises a one-way exhalation flap valve.
According to another aspect of the disclosure, the exhalation valve and the chamber housing are configured to direct exhaled air to vent away from the patient's face.
According to another aspect of the disclosure, at least one air vent is disposed in communication with the exhalation valve.
According to another aspect of the disclosure, the at least one air vent is located on an exterior sidewall of the chamber housing.
According to another aspect of the disclosure, the mouthpiece further comprises a shroud portion configured to cover a side of the output end of the chamber housing and at least partially cover the at least one air vent.
According to another aspect of the disclosure, the at least one air vent is located on the mouthpiece.
According to another aspect of the disclosure, plurality of air vents are disposed around a circumference of the mouthpiece.
According to another aspect of the disclosure, a flow indicator is connected to the inhaler adapter and extends into the interior space of the chamber housing, the flow indicator configured to indicate an inhalation flow rate to the user.
According to another aspect of the disclosure, the flow indicator comprises an audible signaling portion and a visual signaling portion.
According to another aspect of the disclosure, the visual signaling portion is located within an inhalation flowpath.
According to another aspect of the disclosure, the visual signaling portion comprises a pinwheel configured to spin in response to an inhalation airflow.
According to another aspect of the disclosure, the audible signaling portion includes a noisemaker configured to make an audible sound if the inhalation flow rate exceeds a predetermined level.
According to another aspect of the disclosure, the noisemaker may be a whistle.
According to another aspect of the disclosure, the inhaler adapter comprises an inhaler port having a flexible cover.
According to another aspect of the disclosure, the flexible cover comprises an elastomeric wing.
According to another aspect of the disclosure, an aerosol inhalation device for use with an inhaler comprises: an aerosol holding chamber including a housing defining a distal end, a proximal end, and an interior space between the distal and proximal ends configured to hold an administered dose of aerosol from the inhaler; a mouthpiece coupled to the distal end of the housing; an adapter coupled to the proximal end of the housing, the adapter configured to removably couple to the inhaler; and a valve member operable to allow a flow of aerosol to pass from the interior space of the chamber housing to the mouthpiece but not to the atmosphere during inhalation, and further operable to allow a flow of exhaled air to pass from the mouthpiece to the atmosphere but not to the interior space of the chamber housing during exhalation.
According to another aspect of the disclosure, a method of administering a dose of aerosol medication to a patient from a metered-dose inhaler comprises: providing an aerosol inhalation spacer comprising: an aerosol holding chamber including a housing defining a distal end, a proximal end, and an interior space between the distal and proximal ends configured to hold an administered dose of aerosol from the inhaler; a mouthpiece coupled to the distal end of the housing; an adapter coupled to the proximal end of the housing, the adapter configured to removably couple to the inhaler; and a valve member operable to allow a flow of aerosol to pass from the interior space of the chamber housing to the mouthpiece but not to the atmosphere during inhalation, and further operable to allow a flow of exhaled air to pass from the mouthpiece to the atmosphere but not to the interior space of the chamber housing during exhalation; mounting the metered-dose inhaler to the holding chamber by inserting a dispensing portion of the inhaler through an aperture in the adapter; dispensing a dose of the aerosol medication from the metered-dose inhaler into the interior space of the holding chamber to mix with air in the chamber for inhalation by a patient through the mouthpiece.
There has thus been outlined certain aspects of the disclosure in order that the detailed description thereof may be better understood, and in order that the present contribution to the art may be better appreciated. There are additional implementations of the disclosure that will be described below and which form the subject matter of the claims appended hereto.
In this respect, before explaining at least one aspect of the aerosol inhalation device in detail, it is to be understood that the aerosol inhalation device is not limited in its application to the details of construction and to the arrangements of the components set forth in the following description or illustrated in the drawings. The aerosol inhalation device is capable of aspects in addition to those described, and of being practiced and carried out in various ways. Also, it is to be understood that the phraseology and terminology employed herein, as well as the abstract, are for the purpose of description and should not be regarded as limiting.
Implementations of the aerosol inhalation device of the present disclosure are described with reference to the drawings, in which like reference numerals refer to like parts throughout.
The present disclosure provides an aerosol inhalation device or spacer 10 for use with a metered-dose inhaler (MDI) for the administration of aerosolized medication to a patient. Referring to
The holding chamber 20 has a slim profile, such as an oval shaped cross-section, for easy storage and placement within a user's pocket. The holding chamber includes a distal end or output end 21 configured to releasably engage the mouthpiece 50, a proximal end or input end 22 configured to releasably engage the MDI adapter 60, and an interior space 23 between the distal and proximal ends. During operation of the spacer, the distal end 21 represents a downstream portion of the chamber, and the proximal end 22 represents an upstream portion of the chamber.
The mouthpiece 50 is located on the outside of the downstream portion of the chamber and the MDI port 60 is located on the outside of the upstream portion. Turning briefly to
Referring again to
A flow control member 30 is provided on the distal end 21 of the holding chamber 20 and may be integrally formed therewith. In some implementations, the flow control member 30 may be mounted to the distal end 21 of the holding chamber 20. The flow control member 30 is configured to cooperate with the valve member 40 to form a one-way inhalation valve and a one-way exhalation valve. As depicted in
The flow baffle 34 is located centrally on the distal end 21 of the chamber 20 and is operatively attached with the retainer 35 by the connecting members 36. The flow baffle 34 is positioned to partially block the outlet end of the holding chamber 20. As shown in
The flow control member 30 further comprises an expiratory valve seat 29 formed in a side wall of the holding chamber and defining an exhalation port 27 in communication with an exhalation or air vent 28 disposed on a side of the holding chamber 20. The vent 28 includes a rectangular shaped recess or channel formed on an outer surface of the chamber 20 and extending from the distal end 21 of the chamber along a portion of the length of the chamber. In some implementations, a plurality of exhalation vents 28 may be provided. The exhalation vents 28 are located in communication with the one-way exhalation valve in order to avoid the entrainment of ambient air into the mouthpiece 50 during a patient's inhalation of the aerosol medication from the interior space 23 of the chamber 20.
The valve member 40 is configured to allow aerosol medication to be withdrawn through the mouthpiece 50 but prevents backflow into the chamber housing 20. Referring to
The sealing surface 49 of the valve member 40 is configured to sit on the inspiratory valve seat 32 when the device is not in use, as well as when a user exhales through the mouthpiece, such that the annular inner portion 42 covers and blocks the inhalation openings 37. The central opening 41 of the valve member 40 is circular shaped. In some implementations, the central opening 41 may be square shaped, rectangular shaped, triangular shaped, trapezoidal shaped, or elliptical shaped, among others. The valve member 40 may be made of a flexible material such as silicone, a thermoplastic elastomer, or rubber, among others.
The inspiratory valve seat 32 is formed on the outer perimeter of the concave surface of the flow baffle 34. The sealing surface 49 of the valve member 40 is sized and shaped to sealingly meet with the inspiratory valve seat 32. During operation of the spacer, the user actuates the MDI to cause a plume of aerosol medication to be discharged therefrom and into the interior space 23 of the holding chamber 20. The user then inhales the aerosol medication from the interior space 23 via the mouthpiece 50 of the spacer. The act of inhalation causes the annular inner portion 42 of the valve member 40 to move to an open or first position in which the sealing surface 49 of the valve member is lifted from the inspiratory valve seat 32 of the flow control member 30.
Thus, during inhalation, the annular inner portion 42 of the valve member moves in the downstream direction away from the inspiratory valve seat 32 and a gap is created between the sealing surface 49 and the inspiratory valve seat, thus uncovering the inhalation openings 37. In this first position, the outer portion 44 of the valve member is positioned adjacent the retaining ledge 35. Accordingly, the valve member 40 allows aerosol from the interior space 23 to flow through the inhalation openings 37, then through the central opening 41, and then through the mouthpiece 50 to the patient, as illustrated in
Also in this first position, the valve member 40 blocks the exhalation opening 27. In particular, the valve member 40 further comprises an exhalation flow orifice 45 and a peripheral or auxiliary flap 46 extending from a rear surface thereof. The peripheral flap 46 is configured to sealingly sit on the expiratory valve seat 29 and cover the exhalation opening 27 when the spacer is not in use, as well as when a user inhales through the mouthpiece. Thus, during inhalation the peripheral flap 46 covers and blocks the exhalation port 27 to prevent ambient air from being entrained into the aerosol flow within the mouthpiece. The act of exhalation causes the peripheral flap 46 of the valve member 40 to move to an open or second position.
In this second position, as illustrated in
Turning to
The MDI adapter also comprises an ambient air port 68 which opens the interior 23 of the holding chamber 20 to atmosphere so that the user is able to inhale the aerosolized medication dispensed within the chamber once the MDI is activated. The ambient air port 68 may be provided adjacent to the aperture 64 on either side of the adapter 60. The ambient air port 68 is configured to prevent the aerosolized medicine from exiting the interior space of the holding chamber and entering the atmosphere by maintaining a pressure differential therebetween. A flow indicator or breathing indicator 70 is attached to the ambient air port 68.
Referring to
The visual signaling portion 74 helps the user time their inhalation relative to the MDI actuation, and also assists with breath counting. The visual signaling portion may also let the user know whether inhalation should be slowed down. Specifically, a pinwheel 80 or other spinning device, such as a wind spinner, is attached within the passageway of the visual signaling portion 74 about a swivel joint 75. The pinwheel 80 is configured to spin during inhalation as ambient air is drawn into the interior space of the holding chamber through the passageway of the flow indicator 70. The user is able to visibly see how fast the pinwheel 80 spins during inhalation due to the transparency of the holding chamber 20. Accordingly, when the user sees the pinwheel 80 spinning too fast, the user can slow down their breathing as desired. A proper inhalation flow rate of the aerosolized medicine is important because if the user inhales the aerosol too fast it may not be fully effective. During an asthma attack, for instance, if a user inhales the aerosol medicine too fast it may be drawn past the bronchi and into the lungs where it may not have an optimal effect on the user.
In some implementations, a breathing mask may be releasably attached to the mouthpiece 50 via an adapter 50a. As depicted in
Another implementation of an aerosol inhalation device or spacer 100 for use with a metered-dose inhaler (MDI) for the administration of aerosolized medication to a patient is depicted in
The holding chamber 120 has a generally cylindrical or tubular profile. The holding chamber includes a distal end or output end 121 configured to releasably engage the mouthpiece 150, a proximal end or input end 122 configured to releasably engage the MDI adapter 160, and an interior space 123 between the distal and proximal ends. During operation of the spacer, the distal end 121 represents a downstream portion of the chamber, and the proximal end 122 represents an upstream portion of the chamber. In some implementations the holding chamber may have a circular cross-section and be tapered from the proximal end toward the distal end.
The mouthpiece 150 is located on the outside of the downstream portion of the chamber and the MDI port 160 is located on the outside of the upstream portion. Turning briefly to
A distal ledge 125 is formed on the distal end 121 of the holding chamber 120 for sealingly mating with a proximal end 152 of the mouthpiece, and a proximal ledge 126 is formed on the proximal end 122 of the holding chamber for sealingly mating with a distal end 161 of the MDI adapter 160. A locking tab 129 extends from the distal end 121 of the holding chamber for releasably engaging a corresponding retention tab 157 formed on the proximal end 152 of the mouthpiece in a snap-fit manner, as shown in
A flow control member 130 is provided on the distal end 121 of the holding chamber 120 and may be integrally formed therewith. In some implementations, the flow control member 130 may be mounted to the distal end 121 of the holding chamber 120. The flow control member 130 is configured to cooperate with the valve member 140 to form a one-way inhalation valve and a one-way exhalation valve. As depicted in
The flow baffle 134 is located centrally on the distal end 121 of the chamber 120 and is operatively attached with the retainer 135 by the connecting members 136. The flow baffle 134 is positioned to partially block the outlet end of the holding chamber 120. As shown in
As will be discussed in further detail below, a portion of the valve member 140 is configured to sit on an expiratory valve seat 153 located within the proximal end 152 of the mouthpiece 150 to form an exhalation valve having an exhalation port 127. The exhalation port 127 is in communication with an exhalation channel 155 annularly disposed within the proximal end of the mouthpiece. An exhalation or air vent 158 is disposed on a side of the mouthpiece 150 and is in fluid communication with the exhalation channel 155. The exhalation vent 158 may be a hole formed on the proximal end of the mouthpiece 150. In some implementations, a plurality of exhalation vents 158 in communication with the annular exhalation channel 155 may be located annularly around a circumference of the proximal end of the mouthpiece to prevent accidental blockage during use. The exhalation vents 158 are located in fluid communication with the one-way exhalation valve in order to avoid the entrainment of ambient air into the mouthpiece 150 during a patient's inhalation of the aerosol medication from the interior space 123 of the chamber 120.
The valve member 140 is configured to allow aerosol medication to be withdrawn through the mouthpiece 150 but prevents backflow into the chamber housing 120. Referring to
The sealing surface 149 of the valve member 140 is configured to sit on the inspiratory valve seat 132 when the device is not in use, as well as when a user exhales through the mouthpiece, such that the annular inner portion 142 covers and blocks the inhalation openings 137. The central opening 141 of the valve member 140 is circular shaped. In some implementations, the central opening 141 may be square shaped, rectangular shaped, triangular shaped, trapezoidal shaped, or elliptical shaped, among others. The valve member 140 may be made of a flexible material such as silicone, a thermoplastic elastomer, or rubber, among others.
The inspiratory valve seat 132 is formed on the outer perimeter of the flow baffle 134. The sealing surface 149 of the valve member 140 is sized and shaped to sealingly meet with the inspiratory valve seat 132. During operation of the spacer, the user actuates the MDI to cause a plume of aerosol medication to be discharged therefrom and into the interior space 123 of the holding chamber 120. The user then inhales the aerosol medication from the interior space 123 via the mouthpiece 150 of the spacer. The act of inhalation causes the annular inner portion 142 of the valve member 140 to move to an open or first position in which the sealing surface 149 of the valve member is lifted from the inspiratory valve seat 132 of the flow control member 130.
Thus, during inhalation, the annular inner portion 142 of the valve member moves in the downstream direction away from the inspiratory valve seat 132 and a gap is created between the sealing surface 149 and the inspiratory valve seat, thus uncovering the inhalation openings 137. In this first position, the outer portion 144 of the valve member is positioned adjacent the retaining ledge 135. Accordingly, the valve member 140 allows aerosol from the interior space 123 to flow through the inhalation openings 137, then through the central opening 141, and then through the mouthpiece 150 to the patient, as illustrated in
Also in this first position, the valve member 140 blocks the exhalation opening 127. In particular, the valve member 140 further comprises a peripheral or auxiliary flap 146 extending from a front surface thereof. The peripheral flap 146 is configured to sealingly sit on the expiratory valve seat 153 and cover the exhalation opening 127 when the spacer is not in use, as well as when a user inhales through the mouthpiece. Thus, during inhalation the peripheral flap 146 covers and blocks the exhalation port 127 to prevent ambient air from being entrained into the aerosol flow within the mouthpiece. The act of exhalation causes the peripheral flap 146 of the valve member 140 to move to an open or second position.
In this second position, as illustrated in
Turning to
The MDI adapter also comprises an ambient air port 168 which exposes the interior 123 of the holding chamber 120 to atmosphere so that the user is able to inhale the aerosolized medication dispensed within the chamber once the MDI is activated. The ambient air port 168 may be provided adjacent to the aperture 164 on either side of the adapter 160. The ambient air port 168 is configured to prevent the aerosolized medicine from exiting the interior space of the holding chamber and entering the atmosphere by maintaining a pressure differential therebetween. A flow indicator or breathing indicator 170 is attached to the ambient air port 168.
Referring to
The visual signaling portion comprises a pinwheel 180 or other spinning device, such as a wind spinner, that is attached to the visual signaling portion 174 about a swivel joint 175. The pinwheel 180 is configured to spin during inhalation as ambient air is drawn into the interior space of the holding chamber through the passageway of the flow indicator 170. The user is able to visibly see how fast the pinwheel 180 spins during inhalation due to the transparency of the holding chamber 120. Accordingly, when the user sees the pinwheel 180 spinning too fast, the user can slow down their breathing as desired. A proper inhalation flow rate of the aerosolized medicine is important because if the user inhales the aerosol too fast it may not be fully effective. During an asthma attack, for instance, if a user inhales the aerosol medicine too fast it may be drawn past the bronchi and into the lungs where it may not have an optimal effect on the user. Thus, the visual signaling portion 174 helps the user time their inhalation relative to the MDI actuation, and also assists with breath counting. The visual signaling portion may also let the user know whether inhalation should be slowed down.
In some implementations, a breathing mask may be releasably attached to the mouthpiece 150 via an adapter 150a. As depicted in
While various features of the present disclosure may be described with respect to MDI devices, the present disclosure is not limited to such MDI devices. The spacer of the present disclosure may be used with a wide variety of inhaler devices.
While the aerosol inhalation device has been described in terms of what may be considered to be specific aspects, the present disclosure is not limited to the disclosed aspects. Moreover, the many features and advantages of the disclosure are apparent from the detailed specification, and thus, it is intended by the appended claims to cover all such features and advantages of the disclosure which fall within the spirit and scope of the disclosure. Further, it is not desired to limit the disclosure to the exact construction and operation illustrated and described, and accordingly, all suitable modifications and equivalents may be resorted to, falling within the scope of the disclosure. Accordingly, the present disclosure should be considered as illustrative and not restrictive. As such, this disclosure is intended to cover various modifications and similar arrangements included within the spirit and scope of the claims, which should be accorded their broadest interpretation so as to encompass all such modifications and similar structures.
This application claims the benefit of priority to U.S. Provisional Patent Application No. 62/680,923 filed Jun. 5, 2018, the content of which is incorporated herein by reference in its entirety.
Number | Name | Date | Kind |
---|---|---|---|
3837341 | Bell | Sep 1974 | A |
4470412 | Nowacki et al. | Sep 1984 | A |
4534343 | Nowacki et al. | Aug 1985 | A |
4852561 | Sperry | Aug 1989 | A |
5012803 | Foley et al. | May 1991 | A |
5012804 | Foley et al. | May 1991 | A |
5042467 | Foley | Aug 1991 | A |
5385140 | Smith | Jan 1995 | A |
5427089 | Kraemer | Jun 1995 | A |
5522380 | Dwork | Jun 1996 | A |
5584285 | Salter et al. | Dec 1996 | A |
5598835 | von Schrader | Feb 1997 | A |
5724962 | Vidgren et al. | Mar 1998 | A |
5816240 | Komesaroff | Oct 1998 | A |
5842468 | Denyer et al. | Dec 1998 | A |
5848588 | Foley et al. | Dec 1998 | A |
5881718 | Mortensen et al. | Mar 1999 | A |
6026807 | Puderbaugh | Feb 2000 | A |
6039042 | Sladek | Mar 2000 | A |
6176234 | Salter et al. | Jan 2001 | B1 |
6176237 | Wunderlich et al. | Jan 2001 | B1 |
6202643 | Sladek | Mar 2001 | B1 |
6240917 | Andrade | Jun 2001 | B1 |
6257231 | Shick et al. | Jul 2001 | B1 |
6293279 | Schmidt et al. | Sep 2001 | B1 |
6345617 | Engelbreth et al. | Feb 2002 | B1 |
6363932 | Forchione et al. | Apr 2002 | B1 |
6435177 | Schmidt et al. | Aug 2002 | B1 |
6539939 | Rubin | Apr 2003 | B2 |
6557549 | Schmidt et al. | May 2003 | B2 |
6578571 | Watt | Jun 2003 | B1 |
6606990 | Stapleton et al. | Aug 2003 | B2 |
6615826 | Gabrio et al. | Sep 2003 | B1 |
6681768 | Haaije de Boer et al. | Jan 2004 | B2 |
6698422 | Fugelsang et al. | Mar 2004 | B2 |
6712070 | Drachmann et al. | Mar 2004 | B2 |
6848443 | Schmidt et al. | Feb 2005 | B2 |
6904908 | Bruce | Jun 2005 | B2 |
6932082 | Stein | Aug 2005 | B2 |
6962151 | Knoch et al. | Nov 2005 | B1 |
7013896 | Schmidt | Mar 2006 | B2 |
7107987 | Sundaram et al. | Sep 2006 | B2 |
7131440 | Sonntag | Nov 2006 | B2 |
7178518 | Watt et al. | Feb 2007 | B2 |
7201164 | Grychowski et al. | Apr 2007 | B2 |
7201165 | Bruce et al. | Apr 2007 | B2 |
7360537 | Snyder et al. | Apr 2008 | B2 |
7418962 | Rao | Sep 2008 | B1 |
7562656 | Gallem et al. | Jul 2009 | B2 |
7686016 | Wharton et al. | Mar 2010 | B2 |
7748385 | Lieberman | Jul 2010 | B2 |
7849853 | Grychowski et al. | Dec 2010 | B2 |
8061352 | Grychowski et al. | Nov 2011 | B2 |
8074641 | Gallem et al. | Dec 2011 | B2 |
8074642 | Bruce et al. | Dec 2011 | B2 |
RE43174 | Schmidt et al. | Feb 2012 | E |
8151794 | Meyer et al. | Apr 2012 | B2 |
8459252 | Gallem et al. | Jun 2013 | B2 |
8550067 | Bruce et al. | Oct 2013 | B2 |
8770188 | Stenzler | Jul 2014 | B2 |
RE45068 | Schmidt et al. | Aug 2014 | E |
8875697 | Denyer et al. | Nov 2014 | B2 |
8875706 | Meyer et al. | Nov 2014 | B2 |
8905020 | Eagle | Dec 2014 | B2 |
8910625 | Mullinger et al. | Dec 2014 | B2 |
8973571 | Gallem et al. | Mar 2015 | B1 |
9308335 | Gallem et al. | Apr 2016 | B2 |
9352107 | Von Hollen et al. | May 2016 | B2 |
9364621 | Von Hollen et al. | Jun 2016 | B2 |
9364622 | Steelman et al. | Jun 2016 | B2 |
RE46050 | Schmidt et al. | Jul 2016 | E |
9517315 | Meyer et al. | Dec 2016 | B2 |
9555202 | Von Hollen et al. | Jan 2017 | B2 |
9642980 | Alizoti et al. | May 2017 | B2 |
9649455 | Blacker et al. | May 2017 | B2 |
9700688 | Engelbreth et al. | Jul 2017 | B2 |
9700689 | Bruce et al. | Jul 2017 | B2 |
9814849 | Bruce et al. | Nov 2017 | B2 |
9950128 | Meyer et al. | Apr 2018 | B2 |
20070074718 | Austin | Apr 2007 | A1 |
20090013993 | Bird et al. | Jan 2009 | A1 |
20110232636 | Von Hollen et al. | Sep 2011 | A1 |
20120318261 | Newhouse et al. | Dec 2012 | A1 |
20130186393 | Von Hollen et al. | Jul 2013 | A1 |
20130199520 | Dhuper | Aug 2013 | A1 |
20150047635 | Poree | Feb 2015 | A1 |
20160256641 | Lisberg | Sep 2016 | A1 |
20160339187 | Smaldone | Nov 2016 | A1 |
20170028161 | Meyer et al. | Feb 2017 | A1 |
20170232212 | Bruin et al. | Aug 2017 | A1 |
20170252524 | Kruger | Sep 2017 | A1 |
20170296772 | Costella et al. | Oct 2017 | A1 |
20170333645 | Alizoti | Nov 2017 | A1 |
Number | Date | Country |
---|---|---|
2017011865 | Jan 2017 | WO |
2017140599 | Aug 2017 | WO |
Entry |
---|
International Search Report and Written Opinion issued in PCT/US19/35507, dated Aug. 28, 2019. |
Number | Date | Country | |
---|---|---|---|
20190366018 A1 | Dec 2019 | US |
Number | Date | Country | |
---|---|---|---|
62680923 | Jun 2018 | US |